Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) PT at $7.14

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received a consensus rating of “Hold” from the nine analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $7.1429.

A number of brokerages have commented on NMRA. Needham & Company LLC reissued a “buy” rating and set a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday, May 13th. Mizuho increased their target price on Neumora Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th.

Institutional Investors Weigh In On Neumora Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in NMRA. Wells Fargo & Company MN increased its holdings in shares of Neumora Therapeutics by 23.0% in the fourth quarter. Wells Fargo & Company MN now owns 70,653 shares of the company’s stock valued at $749,000 after purchasing an additional 13,196 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Neumora Therapeutics by 254.1% in the fourth quarter. Invesco Ltd. now owns 49,249 shares of the company’s stock valued at $522,000 after purchasing an additional 35,342 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Neumora Therapeutics by 526.4% in the fourth quarter. Legal & General Group Plc now owns 59,842 shares of the company’s stock valued at $634,000 after purchasing an additional 50,289 shares during the last quarter. Barclays PLC increased its holdings in shares of Neumora Therapeutics by 29.1% in the fourth quarter. Barclays PLC now owns 166,822 shares of the company’s stock valued at $1,767,000 after purchasing an additional 37,612 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at approximately $231,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Price Performance

Shares of Neumora Therapeutics stock opened at $1.64 on Friday. The business has a 50 day simple moving average of $1.36 and a two-hundred day simple moving average of $1.16. Neumora Therapeutics has a 12 month low of $0.6110 and a 12 month high of $17.1874. The stock has a market capitalization of $265.60 million, a P/E ratio of -1.04 and a beta of 2.91. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.54 and a quick ratio of 10.54.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Wednesday, August 6th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.05. As a group, analysts predict that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.